323990 — Vaxcell Bio Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- KR₩361bn
- KR₩311bn
- KR₩14m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 13.7 |
Cost of Revenue | |||||
Gross Profit | 0 | 0 | 0 | 0 | 7.13 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 4,011 | 4,255 | 5,904 | 8,217 | 11,520 |
Operating Profit | -4,011 | -4,255 | -5,904 | -8,217 | -11,507 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -1,254 | -3,984 | -4,763 | -6,825 | -10,274 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1,254 | -3,984 | -4,763 | -6,825 | -10,274 |
Net Income Before Extraordinary Items | |||||
Net Income | -1,254 | -3,984 | -4,763 | -6,825 | -10,274 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -1,254 | -3,984 | -4,763 | -6,825 | -10,274 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -111 | -229 | -246 | -350 | -524 |
Dividends per Share |